A Polygenic Risk Score for Prostate Cancer Risk Prediction

Kerry R Schaffer; Mingjian Shi; John P Shelley; Jeffrey J Tosoian; Linda Kachuri; John S Witte; Jonathan D Mosley

doi:10.1001/jamainternmed.2022.6795

A Polygenic Risk Score for Prostate Cancer Risk Prediction

JAMA Intern Med. 2023 Apr 1;183(4):386-388. doi: 10.1001/jamainternmed.2022.6795.

Authors

Kerry R Schaffer^{1

2}, Mingjian Shi³, John P Shelley³, Jeffrey J Tosoian^{2

4}, Linda Kachuri⁵, John S Witte^{5

6}, Jonathan D Mosley^{1

3}

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
³ Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
⁵ Department of Epidemiology and Population Health, Stanford University, Stanford, California.
⁶ Department of Biomedical Data Science and Genetics (by courtesy), Stanford University, Stanford, California.

No abstract available

Plain language summary

This retrospective cohort study compares 2 risk calculator systems that compute the probabilities of finding high-grade or any cancer on biopsy results in men undergoing a first prostate biopsy.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Humans
Male
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / genetics
Risk Factors

Plain language summary

Publication types

MeSH terms

Grants and funding